[Skip to Content]

Vision standards for driving updated April 2013

Apr 12
2013

As part of the suite of Ophthalmic Services Guidance Chapters, this document attempts to address some issues about driving which frequently concern ophthalmologists in their day-to-day work. Rather than reiterating information from the Department for Transport (DfT) and the Driving and Vehicle Licensing Agency (DVLA) which is easily available, either through links in the document

  • 12 April 2013

Response to SMC Decision to accept Eylea for wet AMD

Apr 11
2013

Statement from The Royal College of Ophthalmologists The Royal College of Ophthalmologists welcomes the SMC decision to recommend Aflibercept (Eylea®) as a treatment for neovascular AMD. Aflibercept is a soluble vascular endothelial growth factor (VEGF) receptor fusion protein which binds to all forms of VEGF and inhibits its actions. This drug has been shown in

  • 11 April 2013

Eye health professionals welcome the first ever Public Health Indicator for eye health

Mar 27
2013

Eye health professionals from across the sector will welcome the first ever Public Health Indicator for eye health when it comes into force on April 1st, 2013. As part of the new Public Health Outcomes Framework, the Indicator will track changes in the numbers of people who are certified as blind or partially sighted and

  • 27 March 2013

Cataract shared decision making tool

Mar 11
2013

The Royal College of Ophthalmologists has collaborated with Right Care on a Shared Decision Making Aid to help inform patients about cataracts and treatment options.The new online  tool is accessible on the Shared Decision Making website. The Patient Decision Aids have associated Apps, with versions for Android and Apple devices. Patients can download them from

  • 11 March 2013

Review of ranibizumab in patients with diabetic macular oedema

Mar 07
2013

Statement on the rapid review of the technology appraisal of the use of intravitreal ranibizumab in patients with diabetic macular oedema (DMO) Review of Ranibizumab for DMO

  • 7 March 2013